Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial ...

Jefferies initiated coverage of ANI Pharmaceuticals (ANIP) with a Buy rating and $80 price target The firm expects continued momentum for the shares, driven primarily by Cortrophin Gel and generics.

BMO Capital initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $50 price target The gene therapy company has “two major differences from the typical gene therapy ...

Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.) Proceeds from the new financing transaction will be used to advance the Company's lead therapeutic phage candidates, ...

The 50 GW of new capacity was enough to power approximately 8.5 million households. This growth was accompanied by a significant expansion in domestic solar manufacturing, with module production ...

The companies already have plans to build four plants totaling 5 GW in Texas and mid-Atlantic states. The companies are looking to meet growing power demand for computing and generative artificial ...

The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial ...

DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix ...

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.